# Exscientia

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/exscientia

- Industry: Biotechnology
- Headquarters: Oxford, UK
- Website: www.exscientia.ai
- Total disclosed funding: $306M
- Latest round: Series D (Apr 27, 2021)
- Investors on record: 13

## About

Based in Dundee, UK, and founded in 2012 by its CEO, Andrew Hopkins, Exscientia plc operates as a developer of therapeutic drugs using Artificial Intelligence (AI) and big data processes. The company has offices in Miami, Osaka, and Dundee. Exscientia plc has developed four more candidates that are now undergoing advanced profiling in preparation for IND submission in 2021. In April 2021, the company raised USD 225 million in series D funding from Casdin Capital, Novo Holdings, and SB Investment Advisers. Exscientia trades on Nasdaq under the ticker symbol "EXAI".

Exscientia plc uses AI to design and discover possible medicines. Exscientia plc's centaur chemist platform enables the development of productivity gains and approaches to ameliorate drug potency. The firm's product also outlines small molecules with dual pharmacology, as well as bi-specific small molecules managed by high-content phenotypic information. Exscientia plc has conducted drug discovery partnerships with Bristol-Myers Squibb, Sanofi, Bayer, Dainippon Sumitomo, and other biotech companies.

Exscientia plc plans to use its funding to advance its proprietary pipeline through clinical testing, as well as to continue expanding the technology platform toward autonomous drug design.

## Funding rounds

- Series D, Apr 27, 2021, $223M — Novo Holdings, Marshall Wace, Mubadala Investment Company, Bristol-Myers Squibb Company, BlackRock, Casdin Capital, Laurion Capital Management, Farallon Capital Management, GT Healthcare Capital Partners, SB Investment Advisers, Pivotal Life Sciences, Triatomic Capital
- Series C, May 18, 2020, $59M — Novo Holdings, Evotec SE, Bristol-Myers Squibb Company, GT Healthcare Capital Partners
- Series B, Dec 24, 2018, $24M — Evotec SE, Bristol-Myers Squibb Company, GT Healthcare Capital Partners

## Investors

- Evotec SE — Series B, Series C
- Bristol-Myers Squibb Company — Series B, Series C, Series D
- GT Healthcare Capital Partners (https://capitalatlas.ai/funds/gt-healthcare-capital-partners) — Series B, Series C, Series D
- Novo Holdings — Series C, Series D
- Marshall Wace (https://capitalatlas.ai/funds/marshall-wace) — Series D
- Mubadala Investment Company — Series D
- BlackRock (https://capitalatlas.ai/funds/blackrock) — Series D
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series D
- Laurion Capital Management — Series D
- Farallon Capital Management (https://capitalatlas.ai/funds/farallon-capital-management) — Series D
- SB Investment Advisers (https://capitalatlas.ai/funds/sb-investment-advisers) — Series D
- Pivotal Life Sciences (https://capitalatlas.ai/funds/pivotal-life-sciences) — Series D
- Triatomic Capital (https://capitalatlas.ai/funds/triatomic-capital) — Series D